SCHEMBL622699

SCHEMBL622699

CC(C)COc1cc(N2CCN(C(=O)c3ccc(Cl)c(F)c3)CC2)ncn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 4/20 0.46
ALDH1A1 P00352 3/20 0.42
TACR3 P29371 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA1A P35348 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
PDE2A O00408 1/20 0.39
HTT P42858 2/20 0.38
AURKA O14965 1/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623893 0.89 ALDH1A1 (0.43) MGLLALDH1A1MEN1KMT2ALMNA
SCHEMBL623173 0.87 ALDH1A1 (0.41) MGLLALDH1A1MEN1KMT2ALMNA
SCHEMBL623690 0.87 POLB (0.51) ALDH1A1HRH3MEN1KMT2ALMNA
SCHEMBL624201 0.79 MGLL (0.48) MGLLALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL622237 0.78 HSD17B10 (0.44) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL622643 0.78 CPT2 (0.41) NPSR1
SCHEMBL622642 0.78 CPT2 (0.41) NPSR1
SCHEMBL624044 0.77 CKS1B (0.41) ALDH1A1SMN1; SMN2HTTCYP2C19
SCHEMBL622235 0.77 GPR119 (0.47) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL624185 0.77 KDM4E (0.44) ALDH1A1HRH3MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G MGLL 3566/4885ALDH1A1 2071/4885TACR3 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.